- Report
- May 2024
- 140 Pages
Global
From €6196EUR$6,499USD£5,281GBP
- Report
- February 2024
- 150 Pages
Global
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 90 Pages
Global
From €4528EUR$4,750USD£3,860GBP
- Report
- June 2024
Global
From €6197EUR$6,500USD£5,282GBP
- Report
- February 2024
- 181 Pages
Europe
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 70 Pages
United States
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 90 Pages
Asia Pacific
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 80 Pages
Latin America
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 80 Pages
Europe
From €4528EUR$4,750USD£3,860GBP
- Report
- August 2023
- 150 Pages
North America
From €4528EUR$4,750USD£3,860GBP
- Report
- August 2023
- 70 Pages
Middle East, Africa
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2021
- 500 Pages
United States
From €1945EUR$2,040USD£1,658GBP
€2288EUR$2,400USD£1,950GBP
- Report
- January 2023
- 127 Pages
Global
From €2145EUR$2,250USD£1,828GBP
- Report
- April 2022
- 120 Pages
Global
From €5672EUR$5,950USD£4,835GBP
- Report
- February 2024
- 70 Pages
Indonesia
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 70 Pages
Philippines
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 70 Pages
India
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 70 Pages
Germany
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 70 Pages
Italy
From €4528EUR$4,750USD£3,860GBP
- Report
- February 2024
- 70 Pages
Oman
From €4528EUR$4,750USD£3,860GBP
Trulicity is a medication used to treat type 2 diabetes, a chronic endocrine and metabolic disorder. It is a glucagon-like peptide-1 (GLP-1) receptor agonist, which helps to reduce blood sugar levels by stimulating the release of insulin from the pancreas. Trulicity is administered as a once-weekly subcutaneous injection and is available in both 0.75 mg and 1.5 mg doses. It is also used to reduce the risk of major cardiovascular events, such as heart attack and stroke, in adults with type 2 diabetes and established cardiovascular disease.
Trulicity is part of a larger market of endocrine and metabolic disorder drugs, which includes other GLP-1 receptor agonists, such as Victoza and Bydureon, as well as insulin, sulfonylureas, and thiazolidinediones. These medications are used to treat a variety of endocrine and metabolic disorders, including diabetes, obesity, and thyroid disorders.
Some companies in the Trulicity market include Eli Lilly and Company, Novo Nordisk, Merck & Co., and Sanofi. Show Less Read more